adalimumab

Biocon Biologics Hulio launch, Hulio biosimilar Humira US, Biocon Biologics pricing strategy, Hulio patient-friendly device, Hulio market share US, Biocon Biologics Viatris acquisition, Hulio biosimilar approval FDA,
Latest News Pharma

Biocon Biologicsā€™ CEO reveals pricing strategy and device design for Hulio, its Humira biosimilar, in the US market

Anika Sharma

The competition in the biosimilar arena targeting AbbVie’s blockbuster drug Humira, also known as adalimumab, is heating up. However, for ...

Pharmtales - your go-to source for comprehensive coverage of the pharmaceutical industry.

pharmtales
Latest Pharma News & Insights

Ā© 2025 pharmtales.com | All rights reserved.

PRIVACY POLICY terms of service Contact us